Proposed 2019 Treatment Algorithm for Myeloma

Friday, November 30, 2018
San Diego, California

Friday Satellite Symposium preceding the 60th ASH Annual Meeting & Exposition.

This activity is supported by educational grants from AbbVie; Amgen; Bristol-Myers Squibb; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Image: Copyright©2018 DNA Illustrations. All Rights Reserved
Myeloma: 2019 Algorithms

S. Vincent Rajkumar
Professor of Medicine
Mayo Clinic

Scottsdale, Arizona
Rochester, Minnesota
Jacksonville, Florida
2019 Algorithms

• Clinical Trials preferred
• Only commercially available options
• Assumes all drugs available
Potential New Myeloma or Smoldering Myeloma

Any Myeloma Defining Events?
- CRAB,
- >60% PC,
- FLC >100,
- MRI >1 focal

Treat as Myeloma

No Myeloma Defining Events (SMM)

High Risk SMM
(Median TTP ~2 years)
- Evolving, or
- Many high risk factors
- Consider Treat as Myeloma

Low Risk SMM
(~5% per year PD)
- Clinical Trials
- Observation

When Should Treatment Be Initiated?

Rajkumar SV, Landgren O, Mateos MV. Blood 2015
Myeloma: Frontline Treatment

**Newly Diagnosed MM***

- **Not Transplant Candidate**
  - VRd x 8-12 cycles §
  - R or Rd maintenance

- **Transplant Candidate**
  - VRd § x 3-4 cycles

  - AutoSCT Maintenance (Len for std risk; Bortez for high risk)
  - VRd x 4 cycles

  - Delayed ASCT

*Based on CALGB 100104, S0777, IFM-DFCI, CTN 0702 HOVON

§ VTd/VCd if VRd not available

Rajkumar SV. 2019.
**Myeloma: First Relapse**

- **First Relapse**
  - **Not Refractory to Lenalidomide***
    - DRd
    - KRd
    - Frail: IRd, ERd
  - **Refractory to Lenalidomide**
    - DVd, DPd
    - VCd, KPd, EPd
    - Frail: Pd, IPd

---

*Relapse occurring while off all therapy, or while on small doses of single-agent lenalidomide, or on bortezomib maintenance

¶ Consider salvage auto transplant in eligible patients


Rajkumar SV. 2019.
Myeloma: Second or Higher Relapse

First-Relapse Options

• Any first relapse options that have not been tried
  (2 new drugs; triplet preferred)

Additional Options

• VDT-PACE like regimens
• Melphalan
• Venetoclax (t11;14)
• Bendamustine-based regimens
• Adding Panobinostat
• Quadruplet regimens
Go Online for More Educational Programs on Myeloma!

On-demand Webcast of this symposium, including expert faculty commentary (IMF link below)

Downloadable slides from this symposium (IMF link below)

Interactive Decision Support Tool for myeloma, with personalized expert recommendations for your patients with myeloma

Online programs on caring for your patients with myeloma

myeloma.org/videos/new-strategies-multiple-myeloma-care-next-steps-future
clinicaloptions.com/MyelomaTool
clinicaloptions.com/oncology/topics/Multiple-Myeloma